CMPS vs. TVTX, SAGE, MGNX, NRIX, PRAX, RCKT, CPRX, ZLAB, GLPG, and NAMS
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Travere Therapeutics (TVTX), Sage Therapeutics (SAGE), MacroGenics (MGNX), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Zai Lab (ZLAB), Galapagos (GLPG), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
COMPASS Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Travere Therapeutics received 3 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.92% of users gave COMPASS Pathways an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
COMPASS Pathways has a net margin of 0.00% compared to Travere Therapeutics' net margin of -87.94%. COMPASS Pathways' return on equity of -57.24% beat Travere Therapeutics' return on equity.
Travere Therapeutics has higher revenue and earnings than COMPASS Pathways. Travere Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
In the previous week, Travere Therapeutics had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Travere Therapeutics and 1 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.87 beat Travere Therapeutics' score of 1.17 indicating that COMPASS Pathways is being referred to more favorably in the media.
46.2% of COMPASS Pathways shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
COMPASS Pathways presently has a consensus target price of $47.40, suggesting a potential upside of 542.28%. Travere Therapeutics has a consensus target price of $15.58, suggesting a potential upside of 110.02%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, equities research analysts clearly believe COMPASS Pathways is more favorable than Travere Therapeutics.
Summary
COMPASS Pathways beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
